



October 27, 2016

Genocea to Host Third Quarter 2016 Financial Results Conference Call & Webcast on November 3, 2016

CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 3, 2016 at 9:00 a.m. ET to discuss financial results for the third quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.

Interested participants and investors may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referencing the conference ID number 96207224. To join the live webcast please visit the investor relations section of the Genocea website at <http://ir.genocea.com>.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 30 days.

About Genocea Biosciences Inc.

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended pending further data analysis and consultation with our advisers), and earlier-stage programs in cancer immunotherapy, chlamydia, genital herpes prophylaxis and malaria. For more information, please visit the company's website at www.genocea.com.

For media:

Liz Bryan

Spectrum Science Communications, Inc.

O: 202-955-6222

lbryan@spectrumscience.com

For investors:

Jonathan Poole

Genocea Biosciences, Inc.

O: 617-876-8191

jonathan.poole@genocea.com

 Primary Logo

Source: Genocea Biosciences

News Provided by Acquire Media